JP2023548973A5 - - Google Patents

Info

Publication number
JP2023548973A5
JP2023548973A5 JP2023552149A JP2023552149A JP2023548973A5 JP 2023548973 A5 JP2023548973 A5 JP 2023548973A5 JP 2023552149 A JP2023552149 A JP 2023552149A JP 2023552149 A JP2023552149 A JP 2023552149A JP 2023548973 A5 JP2023548973 A5 JP 2023548973A5
Authority
JP
Japan
Prior art keywords
disease
membrane protein
type
target membrane
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023552149A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548973A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/058291 external-priority patent/WO2022099038A1/en
Publication of JP2023548973A publication Critical patent/JP2023548973A/ja
Publication of JP2023548973A5 publication Critical patent/JP2023548973A5/ja
Pending legal-status Critical Current

Links

JP2023552149A 2020-11-06 2021-11-05 膜タンパク質ターゲティング操作脱ユビキチン化酵素およびその使用方法 Pending JP2023548973A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063110619P 2020-11-06 2020-11-06
US63/110,619 2020-11-06
PCT/US2021/058291 WO2022099038A1 (en) 2020-11-06 2021-11-05 Membrane protein targeting engineered deubiquitinases and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2023548973A JP2023548973A (ja) 2023-11-21
JP2023548973A5 true JP2023548973A5 (cg-RX-API-DMAC7.html) 2024-11-12

Family

ID=81456825

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023552149A Pending JP2023548973A (ja) 2020-11-06 2021-11-05 膜タンパク質ターゲティング操作脱ユビキチン化酵素およびその使用方法

Country Status (7)

Country Link
US (1) US20240002473A1 (cg-RX-API-DMAC7.html)
EP (1) EP4240754A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023548973A (cg-RX-API-DMAC7.html)
CN (1) CN116802198A (cg-RX-API-DMAC7.html)
AU (1) AU2021373873A1 (cg-RX-API-DMAC7.html)
CA (1) CA3200983A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022099038A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026085496A1 (en) * 2024-10-18 2026-04-23 The Trustees Of Columbia University In The City Of New York Compositions and methods for using engineered deubiquitinases for targeted stabilization of voltage-gated sodium channels
CN121471382B (zh) * 2026-01-12 2026-07-24 合肥综合性国家科学中心大健康研究院 去泛素化酶Fc融合蛋白及其产品、制备方法和在苗头化合物筛选中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541074A (en) * 1986-07-25 1996-07-30 The Children's Medical Center Corporation Antibodies to dystrophin and uses therefor
CN101671688A (zh) * 2009-09-25 2010-03-17 上海大学 EGFP融合的β2肾上腺素能受体、其重组表达载体及其构建方法
EP3706782A4 (en) * 2017-11-06 2021-09-08 The Trustees of Columbia University in the City of New York COMPOSITIONS AND METHODS OF USING MANIPULATED DEUBIQUITINASES FOR PROBING UBIQUITIN-DEPENDENT CELL PROCESSES
WO2019126762A2 (en) * 2017-12-22 2019-06-27 The Broad Institute, Inc. Cas12a systems, methods, and compositions for targeted rna base editing
EP3793689A1 (en) * 2018-05-15 2021-03-24 Translate Bio, Inc. Subcutaneous delivery of messenger rna

Similar Documents

Publication Publication Date Title
US20250276000A1 (en) Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
JP6472784B2 (ja) 細胞内在化を誘導するためのcd20結合免疫毒素及びそれを用いる方法
JP2020096630A5 (cg-RX-API-DMAC7.html)
CN111132999A (zh) 支架蛋白
CN110157738B (zh) 靶向cd19和cd22的工程化免疫细胞及其应用
WO2023057946A1 (en) Serum half-life extended pd-l1 binding polypeptides
CN119955743A (zh) 修饰的溶瘤病毒、其组合物和用途
US20240358797A1 (en) Oncoselective cancer therapy
WO2025082038A1 (zh) 靶向保守的HIV gp41亚基近膜端外区的重组干扰素药物及其应用
CN117980465A (zh) 一种用于艾滋病病毒感染基因治疗的基因序列构建体
KR102651002B1 (ko) 인터페론-베타 변이체와 항체가 융합된 재조합 단백질 및 이를 포함하는 약학 조성물
US20260132180A1 (en) Oncoselective therapy
JP2023549761A5 (cg-RX-API-DMAC7.html)
AU2023307937A1 (en) Encrypted rna and methods of its use
CN119490584B (zh) 抗埃博拉病毒VP40蛋白的纳米抗体及其编码mRNA和应用
US20240002473A1 (en) Membrane protein targeting engineered deubiquitinases and methods of use thereof
JP2023549167A5 (cg-RX-API-DMAC7.html)
JP2023551068A5 (cg-RX-API-DMAC7.html)
KR20240165998A (ko) Il2 면역접합체 제조
CN119317430A (zh) 包含委内瑞拉马脑炎(vee)复制子的脂质纳米颗粒及其用途
AU2022339815A1 (en) Antigen recognizing receptors targeting dll3 and uses thereof
EP4520768A1 (en) Vhh-ch3 fusion proteins
EP4548936A1 (en) Antibody-drug conjugates having a tailor-made drug-to-antibody ratio
CN120718913A (zh) 编码双特异性抗体的治疗性多核苷酸
CN120603955A (zh) 具有工程化功能的病毒载体及其生产方法